With the FDA's new plan to consolidate the original reviews of medical products into an integrated review, the academics and researchers, from the most eminent institutes across the globe, have requested the FDA not to move ahead with the new plan with the concern over the misplacement of the valuable information in the original review.

According to the researchers, this sudden movement in the review might mislead the researchers in gathering information from the original review for the process of data collections and studies in clinical trials, which are being submitted to the FDA, along with the other important information, such as post marketing requirements and reviewer concerns with an application, which is believed to be not present in the 'Integrated Review' document.